中文名称 | 地瑞那韦/达芦那韦 |
---|---|
英文名称 | Darunavir (TMC114) |
CAS号 | 206361-99-1 |
分子式 | C₂₇H₃₇N₃O₇S |
分子量 | 547.66 |
外观 | White to off-white powder |
储存条件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Darunavir is a drug used to treat HIV infection. It is in the protease inhibitor class. Darunavir is an orally-bioavailable non-peptidic inhibitor of human immunodeficiency virus type 1 (HIV-1) protease that selectively inhibits HIV-1 protease enzyme induced cleavage of gag and gag-pol poly-proteins preventing the maturation of virions and also inhibits the dimerization of HIV-1 protease suppressing proteolytic activity and subsequent replication of HIV-1. Study results have shown that darunavir exhibits potent inhibition against HIV-1 with a value of 50% inhibition concentration IC50 of 0.003 μmol/L in HIV-1 infected MT-2 cells. Darunavir binds to HIV-1 protease with considerably high affinity and fits closely with the substrate envelop leading to its potent ability to inhibit multidrug-resistant HIV strains. Prezista is an OARAC recommended treatment option for treatment-naïve and treatment-experienced adults and adolescents.
© 2020-2024 凯立德生物医药技术(上海)有限公司 版权所有
沪ICP备15046197号-3
沪公网安备31011502007856号
Designed by Kuanersoft